A Study to Evaluate Abbv-951 in Subjects with Parkinson's Disease (H-47966)
An Open-Label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure to Continuous Subcutaneous Infusion of Abbv-951 in Subjects with Parkinson's Disease.
The purpose of this study is to continue testing whether ABBV-951 is generally safe in subjects with Parkinson's disease after completion of the parent study, M15-741. The study also continues to seek to find out how well ABBV-951 works to control Parkinson's disease symptoms.
ABBV-951 is given as a 24-hour continuous subcutaneous (under the skin) infusion using an infusion pump. Participants are trained on how to operate the pump.
This is an open-label study, which means participants and the study doctor and study staff know that the participant is receiving the ABBV-951.
This study is closed for enrollment.